Steven Cohen Savara Inc Transaction History

Point72 Asset Management, L.P.

$51 Billion
Q3 2025

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Savara Inc stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 419,800 shares of SVRA stock, worth $1.82 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

419,800

Previous 526,162 20.21%

Holding current value

$1.82 Million

Previous $1.2 Million 23.19%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$2.08 - $3.85 $221,232 - $409,493	-106,362 Reduced 20.21%	419,800 $1.48 Million
Q2 2025 Aug 14, 2025	SELL	$1.99 - $3.4 $539,618 - $921,961	-271,165 Reduced 34.01%	526,162 $1.2 Million
Q1 2025 May 15, 2025	BUY	$2.32 - $3.14 $223,508 - $302,507	96,340 Added 13.74%	797,327 $2.21 Million
Q4 2024 Feb 14, 2025	BUY	$2.94 - $4.07 $2.06 Million - $2.85 Million	700,987 New	700,987 $2.15 Million
Q1 2023 May 15, 2023	BUY	$1.6 - $2.82 $3,302 - $5,820	2,064 New	2,064 $4,000

Q2 2020 Aug 14, 2020	SELL	$1.8 - $3.05 $1.63 Million - $2.77 Million	-907,464 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$1.91 - $4.08 $36,481 - $77,928	19,100 Added 2.15%	907,464 $1.92 Million
Q4 2019 Feb 14, 2020	BUY	$0.71 - $4.91 $630,738 - $4.36 Million	888,364 New	888,364 $3.98 Million
Q4 2018 Feb 14, 2019	SELL	$6.27 - $10.92 $4.47 Million - $7.79 Million	-713,000 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$10.49 - $12.87 $7.48 Million - $9.18 Million	713,000 New	713,000 $7.96 Million

Others Institutions Holding SVRA

# of Institutions

132

Shares Held

160M

Call Options Held

14.3K

Put Options Held

24.9K

View Full List

About Savara Inc

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $495M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

More about SVRA

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account